KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Buildings: 2009-2024

Historic Buildings for Teva Pharmaceutical Industries (TEVA) over the last 2 years, with Dec 2024 value amounting to $2.0 billion.

  • Teva Pharmaceutical Industries' Buildings fell 20.90% to $2.0 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $2.0 billion, marking a year-over-year decrease of 20.90%. This contributed to the annual value of $2.0 billion for FY2024, which is 20.90% down from last year.
  • Teva Pharmaceutical Industries' Buildings amounted to $2.0 billion in Q4 2024, which was down 20.90% from $2.5 billion recorded in Q4 2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Buildings registered a high of $2.7 billion during Q4 2020, and its lowest value of $2.0 billion during Q4 2024.
  • Moreover, its 3-year median value for Buildings was $2.5 billion (2022), whereas its average is $2.3 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Buildings grew by 1.02% in 2023 and then fell by 20.90% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Buildings (Quarterly) stood at $2.7 billion in 2020, then declined by 5.59% to $2.6 billion in 2021, then dropped by 4.09% to $2.5 billion in 2022, then grew by 1.02% to $2.5 billion in 2023, then declined by 20.90% to $2.0 billion in 2024.
  • Its last three reported values are $2.0 billion in Q4 2024, $2.5 billion for Q4 2023, and $2.5 billion during Q4 2022.